Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Oktober 2019 06:30 ET | Quelle: Biogen Inc.

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints Based on...
21. Oktober 2019 07:30 ET | Quelle: Biogen Inc.

Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week

Data highlights real-world evidence confirming the safety and efficacy of anti-TNF biosimilars for patients with inflammatory bowel disease (IBD) CAMBRIDGE, Mass. and INCHEON, Korea, Oct. 21, 2019 ...
02. Oktober 2019 07:30 ET | Quelle: Biogen Inc.

Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders

Treatment with SPINRAZA resulted in survival of 100 percent of infants, with none requiring permanent ventilationMotor milestones achieved included 100 percent of participants sitting without support...
01. Oktober 2019 08:00 ET | Quelle: Biogen Inc.

Biogen Announces Leadership Update

Dr. Alfred Sandrock is named Executive Vice President, Research and Development and continues as Chief Medical Officer Dr. Alphonse Galdes appointed Executive Vice President, Pharmaceutical...
23. September 2019 03:00 ET | Quelle: Biogen Inc.

Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding

Positive opinion is supported by data from more than 1,000 real-world pregnancy outcomes Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before...
18. September 2019 07:30 ET | Quelle: Biogen Inc.

Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefitsLong-term data...
17. September 2019 07:30 ET | Quelle: Biogen Inc.

Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has been ranked the #1 biotechnology company on the Dow Jones Sustainability World Index (DJSI...
12. September 2019 05:00 ET | Quelle: Biogen Inc.

New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum

Data highlight benefits of TYSABRI® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and cognitionAn analysis of data...
11. September 2019 05:00 ET | Quelle: Biogen Inc.

New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatmentLatest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen and...
20. August 2019 07:30 ET | Quelle: Biogen Inc.; Invitae Corporation

Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients

New SMA STAT genetic test reduces time to provide results from 21 to four days to aid in clinical careEarly treatment of SMA has been shown to slow disease progression and improve or stabilize loss of...

Vorherige Seite